Welcome to Tokai Pharmaceuticals

Overview | Management | Board of Directors | Medical Advisory Committee

Tokai Pharmaceuticals is a privately held U.S. biopharmaceutical company based in Cambridge, MA, focused on developing new treatments for prostate cancer.

The company’s lead drug candidate, TOK-001, is the first investigational new drug that can decrease overall androgen receptor levels in prostate tumors and in which three distinct mechanisms of action are combined in one drug. TOK-001 is currently in clinical development and is being studied in patients with castration resistant prostate cancer (CRPC).

The company was founded by Apple Tree Partners. In May 2009, Tokai announced that the company closed a $22 million Series D financing round led by the Novartis Venture Fund (NVF). Apple Tree Partners reinvested alongside NVF. Read more about Tokai’s Series D Financing. Tokai’s leadership and medical advisors include the leading experts in prostate cancer.